|
Clinical Trials for Osteosarcoma |
|
|
|
DOGS WITH OSTEOSARCOMA
Eligibility Requirements
• Treatment involves amputation of the affected limb followed by chemotherapy. However, approximately 90% of dogs with OSA will die of spread of disease, usually to the lungs, within 2 years of amputation despite aggressive therapy. If significant improvements in survival time are to occur, new therapeutic approaches need to be explored. Piroxicam is a non-steroidal anti-inflammatory drug that is thought to help inhibit blood vessel growth in tumors by blocking an enzyme called COX-2
Study Objective
The purpose of this study is to compare the combination of piroxicam and cyclophosphamide, with or without Palladia, in dogs with OSA following amputation and standard of care treatment consisting of 4 cycles of carboplatin
Compensation
The study will pay for the carboplatin (total savings of approximately $600-800). The owner will be responsible for all bloodwork, chest x-rays and clinic visit charges during the 4 visits for carboplatin administration. Following initiation of the piroxicam/cyclophosphamide or Palladia/piroxicam/cyclophosphamide maintenance therapy, the owner will be responsible for the piroxicam and cyclophosphamide costs (approximately $50/month) and the costs associated with recheck visits. However, the owner will receive a credit at each recheck visit (approximately $50-75/visit) following initiation of oral therapy totaling $650 over 8 months. Please click on the link for more details.
Location of Trial
Madison, Wisconsin
More information
Exploratory safety study of an intravenous infusion of a novel therapeutic agent for the treatment of melanoma, osteosarcoma, soft tissue sarcoma or squamous cell carcinoma in dogs: A multi-center study
Eligibility Requirements
To qualify for enrollment in this study, dogs must have:
• Histologic or cytologic diagnosis of cancer (biopsy or needle aspirate)
• There is at least 1 tumor (melanoma, osteosarcoma, soft tissue sarcoma, or squamous cell carcinoma) which can be measured (minimum 1 cm in diameter);
• Generally feeling well (i.e. eating, drinking, ambulating on their own, etc.)
• No evidence of an active bacterial infection requiring antibiotics (other than topical medications) in the past 7 days;
• No anti-cancer therapy within the past 21 days. This includes chemotherapy, radiation therapy, prednisone (or other forms of corticosteroids), and immunotherapy; No tumors where abscess (infection) would result in major symptoms
Study Objective
The primary objective of this multi-institutional exploratory study is to describe the safety and efficacy of three dosages of an intravenous infusion of C. novyi-NT spores, with and without concomitant therapy, in dogs with spontaneous tumors.
Compensation
The study sponsor will pay for therapeutic agent, diagnostic tests, and follow-up evaluations. In the event that side effects are noted and attributed to the therapeutic agent, the study will pay for medical management of the side effects. Please click on the link for more details.
Location of Trial
Columbus, OH
More information
Funded Project for Dogs with Osteosarcoma
Eligibility Requirements
• Dogs with suspected primary appendicular Osteosarcoma (based on physical exam or radiographs) or confirmed diagnosis (based on previous cytology or histopathology of the affected limb (+/- metastisis) of appendicular Osteosarcoma with a planned amputation are eligible for this trial.
• An eligible dog must not have received previous treatment for cancer, including chemotherapy, bisphosphonate therapy, prednisone therapy, radiation therapy or immunotherapy, other than Non-Steroid Anti-Inflammatory Drugs (NSAIDs). Concurrent acupuncture is permitted, though the patient must have began acupuncture treatment > 2 weeks prior to sample collection
• (SPECIAL INTEREST IN GREYHOUNDS)
Study Objective
ACI is involved in a clinical trial in which dogs who are scheduled for amputation with a diagnosis of osteosarcoma will have tumor samples collected and analyzed. Dogs of all breed, ages, and sex are eligible. This study serves to evaluate the quality of samples collected from Osteosarcoma bone tumors from dogs for genomic profiling. Samples will be collected following the amputation procedure.
Compensation
TFollowing amputation, patients are eligible to receive treatment as chosen by the owner, including enrollment in another clinical trial. In appreciation of participation, $500 will be provided to the pet owner to offset a portion of the amputation costs. Please click on the link for more details.
Location of Trial
All Metro DC Veterinary Clinics
More information
Impact of Palladia™ on Canine Osteosarcoma
Eligibility Requirements
• Dogs with appendicular osteosarcoma with no radiographic evidence of pulmonary metastasis undergoing amputation
Study Objective
Impact of Palladia™ on Canine Osteosarcoma
Compensation
The study will cover the costs of Palladia and blood work associated with drug monitoring. Clients will be responsible for costs associated with initial evaluation, amputation, and every other month thoracic radiographs (approx. $150/visit). Please click on the link for more details.
Location of Trial
Raleigh, NC
More information
If you have any questions about this study or have a patient that may be eligible, please contact Julie Osborne at 919-513-6812 or email: Julie Osborne or Laurel Williams
Osteosarcoma
Eligibility Requirements
• confirmed Osteosarcoma
• Post amputation
Study Objective
To determine if the addition of NSAIDS will enhance the efficacy of chemotherapies.
Compensation
Non-funded study. Please click on the link for more details.
Location of Trial
West Lafayette, IN
More information
Pathologic fracture risk of tumor-bearing canine antebrachii
Eligibility Requirements
All dogs must be examined by a VMTH oncology, radiation oncology service or soft tissue surgery veterinarian, and require the following baseline evaluations at the owners expense before a dog can be considered for enrollment in the trial:
• Confirmed diagnosis
• Physical examination with weight recorded
• CBC, Chemistry Panel and Urinalysis All within two weeks of enrollment (referring blood work is acceptable as long as it was ran at a commercial lab)
Study Objective
The objective of this study is to measure the reduction in bone strength due to the presence of osteosarcoma in the radius/ulna of the dog by measuring the force at which these bones break in a mechanical testing device. These measurements obtained by testing tumor-bearing bones from clinical patients will be compared to measurements performed in normal bones. Tumor–bearing bones will be obtained from clinical canine patients that are undergoing amputation of the affected limb as standard of care treatment for their bone tumor, and testing of these limbs will not affect care received by these patients. Computed tomography (CT) images of these bones will also be obtained, and this study will seek to correlate calculated CT indices of bone strength with the biomechanically measured bone strength. It is hoped that correlations found will allow prediction of patients at most risk for pathologic fracture, improve patient selection for current treatment options such as palliative radiation therapy, and aid in the development of new minimally invasive limb-salvage procedures.
Compensation
CT of Forelimbs and $325 applied toward total cost of your dog’s anesthesia, which covers the first two hours of anesthesia. This will cover the anticipated time needed to perform the CT imaging (30 minutes) as well as provide a financial benefit to allowing your pet to participate in this study as the remainder of this time will be applied toward your dog’s surgical procedure. Please click on the link for more details.
Location of Trial
Davis, CA
More information
Palladia/Piroxicam/Cyclophosphamide Therapy in Dogs with Osteosarcoma
Eligibility Requirements
• Dogs with osteosarcoma.. please see the website for more details.
Study Objective
The purpose of this clinical trial is to evaluate the activity of iroxicam/cyclophosphamide versus Palladia/piroxicam/cyclophosphamide in dogs with OSA following amputation and standard chemotherapy and to compare this with a historical group of dogs treated with chemotherapy alone.
Compensation
Please click on the link for more details.
Location of Trial
Tinton Falls, NJ
More information
Impact of Palladia/Piroxicam/Cyclophosphamide maintenance therapy on the survival time of dogs with appendicular osteosarcoma following amputation and carboplatin chemotherapy.
Eligibility Requirements
• Dogs with appendicular osteosarcoma treated with amputation are eligible for this study. Dogs must undergo some diagnostic testing prior to starting the study to ensure that they are eligible. They must have good function of liver and kidneys, have acceptable blood cell counts, and are free of metastasis or other severe underlying disease. Prior radiation therapy or chemotherapy for osteosarcoma is not allowed. A 72-hour washout period from steroid or NSAID therapy is required prior to enrollment.
Study Objective
The purpose of this proposal is to perform a randomized clinical trial to determine the impact of Palladia/piroxicam/cyclophosphamide on the disease free interval and overall survival of dogs when administered following amputation and carboplatin chemotherapy.
Compensation
Clients participating in this study will be given special financial considerations. Carboplatin will be provided at no cost to the owner. Once carboplatin therapy is completed, Palladia will be provided by the study and certain pre-determined financial incentives will be given at each recheck visit (up to a total of $650 throughout the course of the study). Please click on the link for more details.
Location of Trial
Fort Collins, CO
Davis, CO
University of Georgia (Athens, Georgia)
Evaluation of a recombinant Listeria monocytogenes vector expressing huHer-2/neu to stimulate anti-tumor immunity and prolong survival times in dogs with appendicular osteosarcoma
Eligibility Requirements
• Only those dogs with a confirmed diagnosis of osteosarcoma (by biopsy) and who have undergone limb amputation and standard chemotherapy (4 doses of carboplatin) for the treatment of osteosarcoma will be eligible for inclusion in the study
• only those patients whose tumors express the target Her-2/neu will be eligible for inclusion in this study.
Study Objective
The Veterinary Clinical Investigations Center is conducting a pilot phase I dose escalation study to determine the dose of a L. monocytogenes expressing huHer-2/neu recombinant vaccine that can effectively stimulate tumor-specific immunity and prolong survival in dogs with osteosarcoma.
Compensation
• Complete staging of disease at the time of enrollment (blood work, urinalysis, immune function assessment, chest x-rays, cardiac evaluation)
• Three Listeria monocytogenes vaccines
• Hospitalization for observation
• Blood work, urinalysis and cardiac evaluation every three weeks for a total of 9 weeks
• Routine staging every 2 months following last vaccine administration (blood work, urinalysis, immune assessment, chest x-rays, cardiac evaluation) There is no cost to participate in this study. Initial diagnosis, amputation and standard of care chemotherapy (carboplatin) and related charges are not covered by the study.
Please click on the link for more details.
Location of Trial
Philadelphia, Pa.
More information
VCIC at 215-573-0302 or vcic@vet.upenn.edu
CycloSam™ (Sm-153-DOTMP) OSA Study
Eligibility Requirements
• Dogs suffering from radiographically-demonstrable osteosarcoma confirmed by biopsy or cytology with ALP staining.
• Adequate renal, hepatic and hematopoietic perimeters with no significant co-morbidities.
• CBC, Chemistry panel, UA, Bone scan and Thoracic radiographs at first visit
• Bone scan must demonstrate adequate uptake of technetium
Study Objective
CycloSam™ (Sm-153-DOTMP) OSA Study is an imaging study that involves an IV injection of a radioisotope (CycloSam™) to assess bone lesion uptake in canine osteosarcoma patients. Patients will receive a palliative dose of CycloSam™ (1 mCi/kg) and be assessed by gamma camera imaging 20-24 hours post-administration. Dogs will be housed in the radiation isolation ward (5-7 days) until their radioactivity has decreased to a level that is acceptable. A secondary endpoint of this study will be subjective assessment of pain palliation.
Compensation
Treatment provided at no cost to the owner. This includes nuclear medicine scans, Cyclosam™, radiation isolation, weekly follow up and blood work +/- chemotherapy. Owners may pursue alternate treatment after bone marrow recovery at their expense. Please click on the link for more details.
Location of Trial
Colombia, MO
More information
Palladia/Piroxicam/Cyclophosphamide Treatment for Dogs with Osteosarcoma
Eligibility Requirements
• Have histologically confirmed diagnosis of OSA
• The disease must be confined to the limb (OSA in areas other than the limbs cannot be included)
• Weigh >10 kgs
• Have undergone limb amputation <14 days prior to treatment initiation (first carboplatin dose)
• Have not received chemotherapy or radiation prior to amputation
• Have corticosteroids or NSAIDs discontinued at least 3 days before the first dose of carboplatin
• Have no evidence of metastatic disease at the time of surgery
Study Objective
Osteosarcoma (OSA) is the most common bone tumor in dogs, occurring in over 8,000 dogs each year in the United States and representing up to 85% of all bone tumors. Treatment involves amputation of the affected limb followed by chemotherapy. To assess the potential impact of this drug on OSA, veterinary oncologists were solicited for cases in which Palladia was used to treat dogs with metastatic OSA. The theory is that the combination of piroxicam and cyclophosphamide (at low doses) will help to inhibit the ability of tumors to grow new blood vessels, thus limiting their ability to grow and spread. There is now data from the human side suggesting that the combination of piroxicam/cyclophosphamide with an inhibitor or VEGFR2 may be better than the two drugs alone.
Compensation
• The study will provide Palladia free of cost for duration of study and beyond
• The study will provide a total of $1,130.00 divided between the visits to help alleviate the costs. That includes paying for the total cost of carboplatin and some of the recheck visits and tests.
Cient Cost
• Owner is responsible for the fees associated with the surgery and costs for each visit that exceed the amount covered by the study per visit.
• Owner is responsible for any additional costs that arise from other medications, and the treatment of potential complications during the study.
Location of Trial
Columbus, OH
More information
CCB02. The National Cancer Institute and UCDAVIS
Eligibility Requirements
• Confirmed diagnosis
• Physical examination with weight recorded
Study Objective
The National Cancer Institute is looking for Golden Retrievers with Lymphoma, Osteosarcoma, Mast Cell Tumors, and Hemangiosarcoma to participate in a clinical trial
Compensation
If your Golden Retriever is eligible for any of the above mentioned cancer types, the study will pay for full-staging (CBC, Chemistry panel, Urine Analysis, Ultrasound, Radiographs) $800-$1000 of staging. This is not a therapy, chemo or drug study. It is a tissue collection study to populate the tissue bank for future research. After your pets surgery you will be instructed to follow-up with an oncologist or your local veterinarian for follow-up care.
Location of Trial
Davis , CA
More information
Naïve Osteosarcoma/Amputated Canine patients with Osteosarcoma that elect not to receive standard IV chemotherapy
Eligibility Requirements
• Confirmed diagnosis
• Physical examination with weight recorded
• CBC, Chemistry Panel and Urinalysis All within two weeks of enrollment (referring blood work is acceptable as long as it was run at a commercial lab)
Study Objective
The goal of this study is to evaluate how well low doses of Gemcitabine control the micro-metastatic disease in the lungs when given as an inhalant.
Compensation
This study is Fully Funded through donations and grants. Once enrolled, the study will pay for office exam, routine bloodwork, and radiographs (while on study). Please note, participation from owner is necessary. Owner is responsible for performing the aerosol treatments at home. Please click on the link for more details.
Location of Trial
Davis, California
More information
Carboplatin vs. Adriamycin Canine pets with Osteosarcoma
Eligibility Requirements
• none
Study Objective
Comparing the two different agents, Carboplatin and Adriamycin
Compensation
There is no financial incentive. We are currently running studies to compare the use of different drugs in different combinations to provide a more effective way of treating various diseases. Your local veterinarian would call us at UCDavis to 'pull an envelope'. Each envelope is randomly pulled comparing the different drug. There is no placebo and it is 'open-label' meaning you will know exactly what drug your pet is receiving. Please click on the link for more details.
Location of Trial
Davis CA
More information
Carboplatin vs. Adriamycin Canine pets with Osteosarcoma
Eligibility Requirements
• none
Study Objective
Comparing the two different agents, Carboplatin and Adriamycin
Compensation
There is no financial incentive. We are currently running studies to compare the use of different drugs in different combinations to provide a more effective way of treating various diseases. Your local veterinarian would call us at UCDavis to 'pull an envelope'. Each envelope is randomly pulled comparing the different drug. There is no placebo and it is 'open-label' meaning you will know exactly what drug your pet is receiving. Please click on the link for more details.
Location of Trial
Davis CA
More information
Relapsed Osteosarcoma/Amputated with metastasis to the lungs
Eligibility Requirements
• Histologically or cytologically confirmed disease
• Amputation
• Visible Metastasis in the Lungs as noted by a radiologist
• Informed owner consent
• Owner must be able to perform treatments at home.
• Return every three weeks for IV treatment of Ifosfamide and bloodwork.
Study Objective
The goal of this study is to evaluate the efficacy of Ifosfamide IV in addition to aerosolized Gemcitabine in dogs with relapsed gross metastatic disease. Eligibility Requirements Any prospective patient must be examined by the VMTH Oncology or Radiation Oncology service veterinarian, and require the following baseline evaluations at the owners expense before a dog can be considered for enrollment in the trial:
Compensation
This study is partially funded. The owner will be responsible for the cost of the Ifosfamide treatment every 3 weeks. The study will pay for every other radiographic evaluation taken while on study. In addition, the cost of the aerosol Gemcitabine is covered under the study. Owner is responsible for performing the aerosol treatments at home. Please click on the link for more details.
Location of Trial
Davis CA
More information
Recombinant L. monocytogenes Vaccine for Dogs with Bone Cancer
Eligibility Requirements
• confirmed diagnosis of osteosarcoma
• tumor expresses the target Her-2/neu
• already undergone limb amputation and 4 doses of carboplatin
Study Objective
Osteosarcoma (bone cancer) is most commonly seen in large and giant breed dogs. It is an aggressive cancer with a guarded prognosis, even when treated with amputation and chemotherapy. The purpose of this study is to determine whether a recombinant L. moncytogenes vaccine can make the dog’s own immune system attack the tumor and prolong survival in dogs with appendicular osteosarcoma The Veterinary Clinical Investigations Center is conducting a pilot phase I dose escalation study to determine the dose of a L. monocytogenes expressing huHer-2/neu recombinant vaccine that can effectively stimulate tumor-specific immunity and prolong survival in dogs with osteosarcoma.
Compensation
The benefits of participating in this study include: - Complete staging of disease at the time of enrollment (blood work, urinalysis, immune function assessment, chest x-rays, cardiac evaluation) - Three Listeria monocytogenes vaccines - Hospitalization for observation - Blood work, urinalysis and cardiac evaluation every three weeks for a total of 9 weeks - Routine staging every 2 months following last vaccine administration (blood work, urinalysis, immune assessment, chest x-rays, cardiac evaluation) Please click on the link for more details
Location of Trial
Philadelphia, PA
More information
Transcatheter Arterial Chemoembolization for the Treatment of Canine Appendicular Osteosarcoma
Eligibility Requirements
• Osteosarcoma confirmed of the distal radius
• No other lesions, confirmed with a bone scan.
• No metastisis of the chest.
Study Objective
The objective of this study is to creat a viable option for the treatment of Osteosarcoma when there are no other viable options.
Compensation
This study is partially funded. Please click on the link for more details.
Location of Trial
Guelph, ON, Canada
More information
Evaluation of pamidronate in the treatment of canine osteosarcoma
Eligibility Requirements
• Dogs with osteosarcoma that have undergone surgery for the removal of the affected limb.
• Must not have pre-existing renal disease.
Study Objective
The goal of this study is to evaluate the tolerability and efficacy of a bisphosphate, pamidronate, given in conjunction with standard of care chemotherapy for dogs with appendicular osteosarcoma post amputation.
Compensation
This study is not funded; so pet owners are responsible for all costs associated with treatment.
Location of Trial
North Grafton, MA
More information
Metronomic chemotherapy in dogs with osteosarcoma
Eligibility Requirements
• Dogs with osteosarcoma that have completed a standard course of chemotherapy after limb amputation.
• Any dog with a life expectancy of less than 1 month or who have lower urinary tract disease are ineligible for this study
Study Objective
The goal of this study is to evaluate for an increased disease free interval in dogs treated with standard of care surgery and chemotherapy followed with maintenance metronomic or low dose chemotherapy.
Compensation
This study is not funded; so pet owners are responsible for all costs associated with treatment.
Location of Trial
North Grafton, MA
More information
Zoledronate for Osteosarcoma
Eligibility Requirements
• Dogs with osteosarcoma of a leg may be eligible for this study.
Study Objective
This clinical trial will test the effectiveness of zoledronate in dogs with appendicular osteosarcoma. The goals of this study include showing that zoledronate is safe, decreases bone decomposition, provides pain management, and delays metastatic disease.
Compensation
This study is partially funded. Please see website for more details.
Location of Trial
Santa Fe, New Mexico
More information
Transtumoral plating as a novel method for palliative limb spare in canine patients with distal radial osteosarcoma: A Pilot Study
Eligibility Requirements
• Dogs with a distal radial osteosarcoma that are free of gross metastatic disease.
• Dogs must have stage IIa osteosarcoma.
Study Objective
To develop a novel surgical method for palliative treatment of canine osteosarcoma of the distal radius. The procedure involves placing a bone plate across the tumor to prevent fracture and decrease pain associated with weight bearing and movement.
Compensation
The cost of this procedure will be significantly less than a traditional limb spare, but there is no financial incentive for enrolling in this study.
Location of Trial
Guelph, Ontario, Canada
More information
Evaluation of efficacy of palliative radiation protocols using force plate analysis in dogs with appendicular osteosarcoma
Eligibility Requirements
• Dogs with osteosarcoma of the limb with no evidence of pulmonary metastasis. (histologic or presumptive radiologic diagnosis)
• Negative for gross metastatic disease on thoracic radiographs +/- long bone survey radiographs/bone scan
• Weight bearing on the affected limb
Study Objective
• The objective evaluation of palliative radiation as a tool for pain management in canine patients with appendicular osteosarcoma using force plate analysis
• The subjective evaluation of palliative radiation as a tool for pain management in canine patients with appendicular osteosarcoma via clinician evaluation and client questionnaires.
• The objective evaluation of two palliative radiation protocols for efficacy in canine appendicular osteosarcoma patients.
• The objective and subjective comparison of patients treated with palliative radiation and analgesics alone versus palliative radiation, analgesics, pamidronate and chemotherapy.
Compensation
This is a partially funded study. Please see website for more details.
Location of Trial
Guelph, Ontario, Canada
More information
Multiple staging techniques for dogs with osteosarcoma
Eligibility Requirements
• Dogs with stage I or II appendicular osteosarcoma that present for staging and treatment
• Dogs will be negative for gross metastatic disease on three-view thoracic radiography
Study Objective
To evaluate the utility of different staging techniques for canine osteosarcoma and determine the tests that are most likely to predict prognosis and optimal treatment. The purpose of this study is to determine the best staging tests for osteosarcoma that will improve our knowledge of prognosis in these cases so that owners can make more informed decisions about treatment.
Compensation
The additional staging tests will be done at no cost to the client. The cost of the initial chest radiographs and bloodwork will be the responsibility of the client. Treatment costs for standard therapy (amputation and chemotherapy) of for palliative radiation will also be the responsibility of the client.
Location of Trial
Guelph, Ontario, Canada
More information
Dogs undergoing limb amputation
Eligibility Requirements
• Dogs that have undergone limb amputation for treatment of osteosarcoma
Study Objective
To evaluate the effectiveness of a new extended release injectable opiod as pain relief for dogs that have undergone limb amputation for the treatment of osteosarcoma.
Compensation
Clients who consent to enroll their dog in the study will receive a $500 discount from their final VMTH bill.
Location of Trial
Madison, WI
More information
Phase Ib study of GS-424044 in dogs with malignant neoplasia
Eligibility Requirements
• Dogs with advanced solid tumors (mainly carcinomas and sarcomas)
• Dogs with tumor type confirmed by histology (for solid tumors)
• Dogs must weigh at least 10.0kg
• Dogs must be otherwise healthy and at least one year of age.
• Have adequate organ function as specified by standard laboratory tests
Study Objective
The purpose of this study is to investigate a new chemotherapy drug as treatment for dos with malignant tumors.
Compensation
This study is partially funded. Please click on link for more details.
Location of Trial
Athens, GA
More information
Liposomal clodronate in canine cancer (excluding mast cell tumor, hemangiosarcoma and malignant histiocytosis)
Eligibility Requirements
• Dogs with biopsy-confirmed cancers (excluding mast cell tumor, hemangiosarcom and malignant histiocytosis) are potentially eligible
• The tumor must be less than 8cm (approximately 3.5 inches) in diameter and located in an easily accessible area for biopsy.
• Dogs must have good function of liver and kidneys and acceptable blood cell counts.
• Dogs must be free of underlying disease.
• OWNERS MUST CONSENT TO A POSTMORTEM EXAM (AUTOPSY) AT THE TIME THEIR PET DIES OR IS EUTHANIZED.
Study Objective
The goals of this study are to demonstrate liposomal clodronate as a safe and effective cancer therapy and to determine the anti-tumor activity of liposomal clodronate against a variety of canine tumors.
Compensation
This study is partially funded. Please click on link for more details.
Location of Trial
Fort Collins, CO
More information
Canine patients with osteosarcoma, lymphoma, or oral malignant melanoma, mast cell tumors, soft tissue sarcomas/histiocytic sarcoma/malignant histiocytosis, primary pulmonary cancer, hemangiosarcomas
Eligibility Requirements
• Requirements vary for each type of cancer listed above. Please click on link for more details.
Study Objective
The goal of the CCOGC and UC Davis will be to populate the Pfizer-CCOGC Biospecimen Repository with diseased tissues and specific normal tissues from dogs with cancer over the next three years.
Compensation
This study is partially funded. Please click on link for more details.
Location of Trial
Davis, CA: More Information
North Grafton, MA: More Information
Madison, WI More Information
Satraplatin for any tumor, including lymphoma
Eligibility Requirements
• Any tumor, including lymphoma confirmed by histopathology or cytology
Study Objective
To determine efficacy of using Satraplatin for various types of cancer using 5mg/m2 daily (orally).
Compensation
This study is partially funded. Please click on link for more details.
Location of Trial
Columbia, MO
More information
Canine Osteosarcoma Study
Eligibility Requirements
• Eligible dogs must have been diagnosed with osterosarcoma by either cytologically or histologically. Patients with local, regional, or systemic metastatic disease are eligible for treatment. Patients with an anticipated survival time without treatment of more than 2 months are required.
Study Objective
Evaluate the clinical response of canine osteosarcoma treated with IL-12 electrogenetherapy with amputation plus standard chemotherapy.
Compensation
Clients participating in this trial will receive a 100% discount for the initial work-up, surgery, standard chemotherapy treatments, and 3 follow-up rechecks.
Location of Trial
Baton Rouge, LA
More information
|
| |
|
